<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Posttransplant <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> is a clinical challenge </plain></SENT>
<SENT sid="1" pm="."><plain>Traditional chemotherapy results in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response, but toxicity and transplant rejection limit survival </plain></SENT>
<SENT sid="2" pm="."><plain>The authors treated seven patients with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> after organ transplant with chemotherapy tailored to individual patient response </plain></SENT>
<SENT sid="3" pm="."><plain>Chemotherapy consisted of <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi>, with or without <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (Adriamycin; Pharmacia &amp; Upjohn, Peapack, NJ, U.S.A.), or the ProMACE-CytaBOM regimen </plain></SENT>
<SENT sid="4" pm="."><plain>Six of seven patients (86%) showed a complete response to treatment, with five of seven (71%) alive disease-free at 9 to 72 months (mean 38.2) after treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The results show that chemotherapy tailored to individual patient response is a safe and effective therapy for malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> arising in patients with posttransplant <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> </plain></SENT>
</text></document>